Document Detail


Antithrombotic therapy in the secondary prevention of myocardial infarction.
MedLine Citation:
PMID:  8279355     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is now convincing evidence that the majority of myocardial infarcts are caused by acute occlusion of the coronary artery with a thrombus, often originating from a ruptured atherosclerotic plaque. The thrombus is composed of both platelets and fibrin, so it is logical to expect that both antiplatelet and anticoagulant therapy would be effective for the prevention of reinfarction and other thrombotic vascular events following myocardial infarction. A review of clinical trials confirms this suggestion. Aspirin is beneficial in that it reduces vascular mortality by about 12% and total vascular events by 25%. Similarly, oral anticoagulants reduce total mortality by up to 20% and vascular events by about 40%. However, relatively few large scale trials of oral anticoagulants after infarction have been carried out, and the confidence intervals are wider than those for the aspirin trials. In practice aspirin is used more widely than oral anticoagulants as it is easier to administer and control. Only one trial (EPSIM) has directly compared oral anticoagulants and aspirin. This trial showed that both drugs had equal efficacy but that compliance with aspirin was better. Finally, the question of giving antiplatelet agents and anticoagulants together, to block both platelet aggregation and fibrin formation, is considered. A preliminary trial in prosthetic heart-valve patients has been encouraging but more large, long-term trials are required before recommendations can be made, as the use of both drugs together carries an increased risk of severe hemorrhage.
Authors:
C R Prentice
Related Documents :
6684535 - Plasminogen activator content in heart tissue and perfusate under various experimental ...
8617465 - Placental changes in a first trimester missed abortion in maternal systemic lupus eryth...
8996255 - Medical issues and emergencies in the dermatology office.
1936005 - Myocardial infarction in a patient with factor xi deficiency and a lupus anticoagulant.
24084625 - Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in st-s...
19338675 - Effects of astragaloside iv on heart failure in rats.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  72     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1993 Dec 
Date Detail:
Created Date:  1994-02-04     Completed Date:  1994-02-04     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  175G-180G     Citation Subset:  AIM; IM    
Affiliation:
Division of Medicine, University of Leeds, General Infirmary, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Fibrinolytic Agents / therapeutic use*
Humans
Myocardial Infarction / prevention & control*
Recurrence
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early and late angiotensin-converting enzyme inhibition in acute myocardial infarction.
Next Document:  Expanding indications for thrombolytic therapy in acute myocardial infarction. How late is too late,...